

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2022 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorials

- 1 Greetings from the editor 2022
J S Smolen
- 4 Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment
D Felson, D Laccaille, M P LaValley, D Aletaha
- 7 Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free?
D G McGonagle, A Zabotti, A Watad, C Bridgewood, G De Marco, A Kerschbaumer, D Aletaha

Review

- 11 Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning
J Braun, U Kiltz, X Baraliakos

Viewpoint

- 15 From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?
I Parodis, F A Houssiau

Recommendations

- 20 EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
G Nagy, N M T Roodenrijs, P M J Welsing, M Kedves, A Hamar, M C van der Goes, A Kent, M Bakkers, P Pchelnikova, E Blaas, L Senolt, Z Szekanez, E H Choy, M Dougados, J W G Jacobs, R Geenen, J W J Bijlsma, A Zink, D Aletaha, L Schoneveld, P van Riel, S Dumas, Y Prior, E Nikiphorou, G Ferraccioli, G Schett, K L Hyrich, U Mueller-Ladner, M H Buch, I B McInnes, D van der Heijde, J M van Laar

- 34 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19

A Alunno, A Najm, P M Machado, H Bertheussen, G-R R Burmester, F Carubbi, G De Marco, R Giacomelli, O Hermine, J D Isaacs, I Koné-Paut, C Magro-Checa, I B McInnes, P L Meroni, L Quartuccio, A V Ramanan, M Ramos-Casals, J Rodríguez Carrio, H Schulze-Koops, T A Stamm, S W Tas, B Terrier, D G McGonagle, X Mariette

Rheumatoid arthritis

- 41 Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
I Redeker, K Albrecht, J Kekow, G R Burmester, J Braun, M Schäfer, A Zink, A Strangfeld
- 48 Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis
F Wouters, M P Maurits, L van Boheemen, M Verstappen, K Mankia, X M E Matthijssen, A L Dorjé, P Emery, R Knevel, D van Schaardenburg, R E M Toes, A H M van der Helm-van Mil

- 56 Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy

A Ibáñez-Costa, C Perez-Sanchez, A M Patiño-Trives, M Luque-Tevar, P Font, I Arias de la Rosa, C Roman-Rodriguez, M^a C Abalos-Aguilera, C Conde, A Gonzalez, S Pedraza-Arevalo, M del Rio-Moreno, R Blazquez-Encinas, P Segui, J Calvo, R Ortega Castro, A Escudero-Contreras, N Barbarroja, M^a A Aguirre, J P Castaño, R M Luque, E Collantes-Estevéz, C Lopez-Pedreira

Psoriatic arthritis

- 68 Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis
P Gisondi, F Bellinato, G Targher, L Idolazzi, G Girolomoni

MORE CONTENTS ►



Member since 2008

J.M00004

This journal is a member of and subscribes to the principles of the

Committee on Publication Ethics

<http://publicationethics.org/>

When you have finished

with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

- 74** Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis

M L Acosta Felquer, L LoGiudice, M L Galimberti, J Rosa, L Mazzuoccolo, E R Soriano

- 80** Does biologic therapy impact the development of PsA among patients with psoriasis?

E Meer, J F Merola, R Fitzsimmons, T J Love, S Wang, D Shin, Y Chen, S Xie, H Choi, Y Zhang, J U Scher, C T Ritchlin, J M Gelfand, A Ogdie

Osteoarthritis

- 87** METTL3-mediated m⁶A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression

X Chen, W Gong, X Shao, T Shi, L Zhang, J Dong, Y Shi, S Shen, J Qin, Q Jiang, B Guo

Systemic lupus erythematosus

- 100** B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial



R A Furie, G Aroca, M D Cascino, J P Garg, B H Rovin, A Alvarez, H Fragoso-Loyo, E Zuta-Santillan, T Schindler, P Brunetta, C M Looney, I Hassan, A Malvar

Systemic sclerosis

- 108** Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease

S M Jung, K-S Park, K-J Kim

Vasculitis

- 117** Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study

X Kong, Y Sun, X Dai, L Wang, Z Ji, H Chen, X Jin, L Ma, L Jiang

- 124** Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis



I R Adriawan, F Atschezkezi, O Dittrich-Breiholz, P Garantziotis, S Hirsch, L M Risser, M Kosanke, R E Schmidt, T Witte, G Sogkas

Epidemiology

- 132** Native joint infections in Iceland 2003–2017: an increase in postarthroscopic infections



S L Gunnlaugsdóttir, H Erlendsdóttir, K O Helgason, Á J Geirsson, V Thors, S Guðmundsson, M Gottfredsson

Letters

- 141** Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA

T Kissel, T J van Wesemael, A Lundquist, H Kokkonen, A Kawakami, M Tamai, D van Schaardenburg, M Wuhler, T WJ Huizinga, H U Scherer, D van der Woude, S Rantapää-Dahlqvist, R E M Toes

- 143** B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics

R Felten, P-M Duret, E Bauer, N Sedmak, J H Djossou, M Bensalem, M Ardizzone, M Geoffroy, A Fan, M Couderc, J H Salmon, L Messer, R-M Javier, A Meyer, E Chatelus, C Sordet, L Pijnenburg, J Fort, M Rinagel, J Walther, C Fabre, L Arnaud, J Sibilia, N Meyer, F Berenbaum, Isabelle Chary-Valckenaere, M Soubrier, J Sellam, J-E Gottenberg

- 145** SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases

S Lawson-Tovey, K L Hyrich, L Gossec, A Strangfeld, L Carmona, B Raffener, G K Yardmca, L Trefond, N Roux, A Rodrigues, C Papagoras, E F Mateus, X Mariette, P M Machado

Electronic pages

- e1** Correspondence on 'Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor' by Ishikawa *et al*

C Regueiro, A Gonzalez

- e2** Response to: 'Correspondence on 'Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor' by Ishikawa *et al*' by Regueiro and Gonzalez

Y Ishikawa, K Ikari, C Terao

- e3** Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study

Y H Lee

- e4** Response to: 'Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by Lee

J Inamo

- e5** Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells

S K Raychaudhuri, C Abria, S P Raychaudhuri

- e6** Response to: 'Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells' by Raychaudhuri *et al*
M Canavan, S M Wade, D J Veale, U Fearon
- e7** Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years
K Parperis
- e8** Response to: 'Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years' by Parperis
X Baraliakos, A Richter, C O Schmidt, J Braun
- e9** Correspondence on: 'Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Wallman *et al*
F Proft, M Protopopov, V Rios Rodriguez, M Torgutalp, B Siegmund, D Poddubnyy
- e10** Response to: 'Correspondence on: irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Proft *et al*.
J K Wallman, E Mogard, J Marsal, K Andréasson, A Jöud, M Geijer, L E Kristensen, E Lindqvist, T Olofsson
- e11** Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease
C Campochiaro, G Cavalli, N Farina, A Tomelleri, G De Luca, L Dagna
- e12** Response to: 'Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease' by Campochiaro *et al*
F Cohen-Aubart, N Benameur, Z Amoura, J Haroche
- e13** Correspondence on 'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation' by Braaten *et al*
F Ceccarelli, A Botticelli, A J Gelibter, I Leccese, R Lucchetti, E Cortesi, G Valesini, P Marchetti, F Conti
- e14** Response to: Correspondence on "Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation" by Braaten *et al*
L C Cappelli, C O Bingham, T Braaten, A A Shah
- e15** Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?
A Fayand, V Hentgen, S Ducharme-Bénard, P Quartier, B Bader-Meunier, I Koné-Paut, G Grateau, S Georgin-Lavialle
- e16** Response to: 'Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?' by Fayand *et al*
M Gattorno, M Hofer, F Vanoni, S Federici, L Cantarini, N Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever Registry
- e17** Correction: *Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis*